Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial건강한 성인의 코로나바이러스 질병 2019에 대한 재조합 융합 단백질 백신(V-01)의 면역원성과 안전성: 무작위 배정, 이중 맹검, 위약 대조, 2상 시험Clinical Trial Published on 2021-07-222022-09-12 Journal: Chinese medical journal [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome Adults adverse event AEs age anti-RBD Antigen appear China clinical trial clinical trials confidence interval Control convalescent serum coronavirus coronavirus disease COVID-19 COVID-19 patient demonstrated distribution dose regimen dosing regimens double-blind Efficacy elevated Endpoint Frequency fusion protein geometric mean titer group Guangdong healthy IFN-PADRE-RBD-Fc dimer immune response immune responses immunization immunogenic immunogenicity Immunoglobulin imperative indicated initiated injection intramuscularly less mild in severity neutralizing antibody Older pandemic participant peaked percentage Phase I Placebo placebo-controlled Preliminary data preliminary finding prevention primary immunogenicity Randomized RBD reactogenicity receive Receptor binding domain recombinant COVID-19 vaccine recombinant fusion protein recruited regimen remained robust Safe safety profile significantly specific binding antibody Support symptomatic Trial two-dose regimen V-01 Vaccine vaccine candidate Vaccines [DOI] 10.1097/CM9.0000000000001702 PMC 바로가기 [Article Type] Clinical Trial
Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposingCOVID-19에 대한 클로로퀸과 하이드록시클로로퀸: 용도 변경 실패에 대한 전망Review Published on 2021-02-012022-09-11 Journal: Journal of clinical pharmacy and therapeutics [Category] Coronavirus, 신약개발, 치료제, [키워드] adverse effect antiviral activities Azithromycin balance Chloroquine choice clinical evidence Clinical studies clinical trial clinically COVID-19 COVID-19 infection COVID-19 patient dose Dose-response doses dosing regimens drug effective Efficacy effort Endpoint Evidence focus HCQ Hydroxychloroquine Infection interleukin interleukin-6 International National not effective Patient patients with COVID-19 Perspective phobia Prophylaxis proportion QT interval QTc interval question receiving recent reduction in regimen Result resulting risk therapeutic potential threshold Viral viral infections Viral load [DOI] 10.1111/jcpt.13267 PMC 바로가기 [Article Type] Review
Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedemaArticle Published on 2020-12-162022-10-04 Journal: Scientific Reports [Category] 바이오마커, [키워드] analysed baseline changes clinical trial comparable Diabetic Diseases dosing regimens Efficacy eye FIVE fixed flexible Health care injection Injections intravitreal injection Medical research multicentre oedema outcome Patient patients reduced regimen severity single-arm visual acuity visual impairment was performed [DOI] 10.1038/s41598-020-78954-3 PMC 바로가기 [Article Type] Article
It is time to drop hydroxychloroquine from our COVID-19 armamentariumCOVID-19 무기고에서 하이드록시클로로퀸을 중단할 때입니다.Article Published on 2020-11-012022-09-11 Journal: Medical Hypotheses [Category] SARS, 비임상, 신약개발, 임상, 치료제, [키워드] anti-SARS-CoV-2 activities Antiviral Blood breath cardiac toxicity catalyzed Chloroquine claimed conducted COVID-19 COVID-19 disease cumulative dose dosing regimens drug drug concentration Drug-drug interactions effective Efficacy epidemiological Evidence evidence of exhibited HCQ Hydroxychloroquine in vitro in vitro study in vivo increased risk influence interferon response lack mechanism media molecular mechanism molecular mechanisms observation observational studies observational study ongoing trial outcome Patient Perspective pharmacological preventing infection Prophylaxis randomized trial receive recruit SARS-COV-2 infection therapeutic potential Treatment treatment initiation widespread [DOI] 10.1016/j.mehy.2020.110198 PMC 바로가기 [Article Type] Article
Assay validation and determination of in vitro binding of mefloquine to plasma proteins from clinically normal and FIP-affected catsResearch Article Published on 2020-08-052022-10-28 Journal: PLoS ONE [Category] Coronavirus, MERS, [키워드] Accuracy antimalarial Antiviral average binding calicivirus clinical trial clinically coefficient Concentration coronavirus demonstrated detect dialysis dosing regimens expressed in vitro in vivo infections inhibit investigated limit plasma plasma concentration plasma protein Plasma Protein Binding Population Precision proportion Proteins quantification reported Standard deviation Variation [DOI] 10.1371/journal.pone.0236754 PMC 바로가기 [Article Type] Research Article
Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2SARS CoV-2에 감염된 환자의 잠재적인 항바이러스 치료 인도메타신의 투여 요법을 추정하기 위한 모델 기반 접근 방식Original Paper Published on 2020-05-202022-09-10 Journal: Journal of Pharmacokinetics and Pharmacodynamics [Category] MERS, SARS, 비임상, [키워드] administration anti-inflammatory drug antiviral activity antiviral property Antiviral treatment approach assumption benefit best breath canine Clinical dose Complete coronavirus criteria dosage dose dosing regimen dosing regimens drugs effective evaluated expected Human human SARS-CoV-2 identify In-vitro indomethacin Model Model-based Patient Prospective clinical trial regimen SARS CoV-2 SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 coronavirus SARS-CoV-2 pandemic shown supplementary material the SARS-CoV-2 therapeutic effect Translational model Treatment Viral Viral load [DOI] 10.1007/s10928-020-09690-4 PMC 바로가기 [Article Type] Original Paper